A newer KRAS G12C drug lengthens progression-free time in lung cancer

A next-generation KRAS G12C inhibitor reportedly extends the time lung cancer patients live without progression, per Nature Medicine.

A report in Nature Medicine describes a next-generation KRAS G12C inhibitor that improves survival in lung cancer, extending the time patients live without their disease progressing. KRAS G12C is a common mutation in lung cancer, and targeted drugs aimed at it are the treatment approach in question.

This is a health story because each better option for a common mutation widens who can be treated effectively. Targeted therapies work by matching a drug to a specific genetic change in the tumor, so improvements in this class can give more patients a longer period of controlled disease. Whether a newer drug becomes broadly affordable and accessible is a separate question, and one to watch as it moves toward wider use.

The full account, including trial design, the size of the benefit and safety findings, sits with the source.

Source: Nature Medicine